Glancy Prongay & Murray LLP Commences Investigation on Behalf of Boston Scientific Corporation Investors

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors concerning the Company and its officers’ possible violations of federal securities laws.

On February 23, 2017, Boston Scientific disclosed the voluntary recall of the Company’s Lotus Valve heart devices. Citing issues with the premature release of a pin, Boston Scientific believes the problem is due to "excess tension in the pin mechanism introduced during the manufacturing process". Additionally, the Company doesn’t expect to bring the product back to market until the fourth quarter of 2017.

On this news, shares of Boston Scientific fell as much as 7% during intraday trading on February 23, 2017.

If you purchased Boston Scientific securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170224005120/en/